Research programme: diabetes therapy - MediGene LtdAlternative Names: HiDex
Latest Information Update: 30 Aug 2010
At a glance
- Originator Avidex
- Developer MediGene Ltd
- Mechanism of Action Immunomodulators; T lymphocyte inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 29 Sep 2006 Avidex has been acquired by MediGene AG
- 01 Nov 2005 Preclinical trials in Type-1-diabetes-mellitus in United Kingdom (unspecified route)